Nonsuperiority of Technetium-99M-galactosyl Human Serum Albumin Scintigraphy over Conventional Volumetry for Assessing the Future Liver Remnant in Patients Undergoing Hepatectomy after Portal Vein Embolization.

Background: Technetium-99m-galactosyl human serum albumin scintigraphy is preferred for assessing the liver functional reserve in patients undergoing hepatectomy, but its superiority over computed tomography volumetry after portal vein embolization and subsequent hepatectomy remains elusive. We aimed to compare technetium-99m-galactosyl human serum albumin scintigraphy with conventional computed to-mography volumetry for predicting posthepatectomy liver failure in patients after portal vein embolization.Methods: This retrospective study analyzed 152 consecutive patients who underwent hepatobiliary cancer resection after portal vein embolization between 2006 and 2021. Posthepatectomy liver failure was graded according to the International Study Group of Liver Surgery criteria. The predictive abilities for posthepatectomy liver failure were compared between the future remnant uptake (%) by technetium-99m-galactosyl human serum albumin scintigraphy and the future remnant volume (%) by computed tomography volumetry. Results: Future remnant uptake (%) was significantly greater than future remnant volume (%) after portal vein embolization (47.9% vs 40.8%; P < .001), while the values were comparable before portal vein embolization (32.7% vs 31.2%; P = .116). Receiver operating characteristic curve analysis revealed that post-portal vein embolization future remnant volume (%) had a significantly higher area under the curve than post-portal vein embolization future remnant uptake (%) (0.709 vs 0.630; P = .046) for predicting posthepatectomy liver failure. Multivariable analysis revealed that post-portal vein embolization future remnant volume (%) independently predicted posthepatectomy liver failure, but future remnant uptake (%) did not. Although the incidence of posthepatectomy liver failure grade >= B was 17.8% when indoc-yanine green-clearance of the future liver remnant based on both future remnant volume (%) and future remnant uptake (%) was >= 0.05, it was higher in other combinations: 55.6% for indocyanine green clearance of the remnant volume >= 0.05/indocyanine green clearance of the remnant uptake <= 0.05; 50.0% for indocyanine green clearance of the remnant volume <= 0.05/indocyanine green clearance of the remnant uptake >= 0.05; and 50% for indocyanine green clearance of the remnant volume <= 0.05/indoc-yanine green clearance of the remnant uptake <= 0.05.Conclusions: Technetium-99m-galactosyl human serum albumin scintigraphy is not superior to computed tomography volumetry for assessing the future liver remnant in patients undergoing major hepatectomy after portal vein embolization.(c) 2022 Elsevier Inc. All rights reserved.